1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Pharmacology and Toxicology
  4. Volume 64, 2024
  5. Article

Annual Review of Pharmacology and Toxicology

Volume 64, 2024

Alcohol Use Disorder Treatment: Problems and Solutions

Abstract

Alcohol use disorder (AUD) afflicts over 29 million individuals and causes more than 140,000 deaths annually in the United States. A heuristic framework for AUD includes a three-stage cycle—binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation—that provides a starting point for exploring the heterogeneity of AUD with regard to treatment. Effective behavioral health treatments and US Food and Drug Administration–approved medications are available but greatly underutilized, creating a major treatment gap. This review outlines challenges that face the alcohol field in closing this treatment gap and offers solutions, including broadening end points for the approval of medications for the treatment of AUD; increasing the uptake of screening, brief intervention, and referral to treatment; addressing stigma; implementing a heuristic definition of recovery; engaging early treatment; and educating health-care professionals and the public about challenges that are associated with alcohol misuse. Additionally, this review focuses on broadening potential targets for the development of medications for AUD by utilizing the three-stage heuristic model of addiction that outlines domains of dysfunction in AUD and the mediating neurobiology of AUD.

Keyword(s): alcohol use disorder, AUD, AUD treatment, AUD treatment gap, brief intervention and referral to treatment, neurobiology of AUD, screening, stigma
Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-031323-115847
2024-01-23
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/64/1/annurev-pharmtox-031323-115847.html?itemId=/content/journals/10.1146/annurev-pharmtox-031323-115847&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Subst. Abuse Ment. Health Serv. Admin 2021. Table 5.1A—substance use disorder for specific substances in past year: among people aged 12 or older; by age group, numbers in thousands. 2021 Natl. Survey Drug Use Health (NSDUH) Subst. Abuse Ment. Health Serv. Admin., Dep. Health Hum. Serv. Rockville, MD: https://www.samhsa.gov/data/sites/default/files/reports/rpt39441/NSDUHDetailedTabs2021/NSDUHDetailedTabs2021/NSDUHDetTabsSect5pe2021.htm
    [Google Scholar]
  2. 2.
    CDC (Cent. Dis. Control Prev.) 2022. Deaths from excessive alcohol use in the United States. Centers for Disease Control and Prevention https://www.cdc.gov/alcohol/features/excessive-alcohol-deaths.html
    [Google Scholar]
  3. 3.
    Deutsch-Link S, Jiang Y, Peery AF, Barritt AS, Bataller R, Moon AM. 2022. Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic. Clin. Gastroenterol. Hepatol. 20:2142–44.e2
     [Google Scholar]
  4. 4.
    Sohal A, Khalid S, Green V, Gulati A, Roytman M. 2022. The pandemic within the pandemic: unprecedented rise in alcohol-related hepatitis during the COVID-19 pandemic. J. Clin. Gastroenterol. 56:e171–75
     [Google Scholar]
  5. 5.
    White AM, Castle IP, Powell PA, Hingson RW, Koob GF. 2022. Alcohol-related deaths during the COVID-19 pandemic. JAMA 327:1704–6
     [Google Scholar]
  6. 6.
    Koob GF, Powell P, White A. 2020. Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19. Am. J. Psychiatry 177:1031–37
     [Google Scholar]
  7. 7.
    Koob GF, Arends MA, McCracken M, Le Moal M, eds. 2021. Neurobiology of Addiction, Vol. 3: Alcohol New York: Elsevier
     [Google Scholar]
  8. 8.
    Am. Psychiatr. Assoc 2013. Diagnostic and Statistical Manual of Mental Disorders Washington, DC: Am. Psychiatr. Publ. 5th ed.
  9. 9.
    Koob GF, Arends MA, McCracken M, Le Moal M, eds. 2019. Neurobiology of Addiction, Vol. 1: Introduction to Addiction New York: Elsevier
     [Google Scholar]
  10. 10.
    Koob GF, Le Moal M 1997. Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58
     [Google Scholar]
  11. 11.
    Ballantyne J, Sullivan MD, Koob GF. 2019. Refractory dependence on opioid analgesics. Pain 160:2655–60
     [Google Scholar]
  12. 12.
    Koob GF. 2021. Drug addiction: hyperkatifeia/negative reinforcement as a framework for medications development. Pharmacol. Rev. 73:163–201
     [Google Scholar]
  13. 13.
    Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35:217–38. Erratum. 2010. Neuropsychopharmacology 35:1051
    [Google Scholar]
  14. 14.
    Koob GF, Volkow ND. 2016. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–73
     [Google Scholar]
  15. 15.
    Shurman J, Koob GF, Gutstein HB. 2010. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med. 11:1092–98
     [Google Scholar]
  16. 16.
    Witkiewitz K, Litten RZ, Leggio L. 2019. Advances in the science and treatment of alcohol use disorder. Sci. Adv. 5:eaax4043
     [Google Scholar]
  17. 17.
    Kelly JF, Humphreys K, Ferri M. 2020. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst. Rev. 3:CD012880
     [Google Scholar]
  18. 18.
    Mason BJ, Goodman AM. 2005. Alcoholfree therapist's manual Manual, Pearson Cent. Alcohol Addict. Res. La Jolla, CA: http://www.pearsoncenter.org/therapistmanual
  19. 19.
    Miller WR, Zweben A, DiClemente CC, Rychtarik RG. 1995. Motivational enhancement therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence Proj. MATCH Monogr. 2, US Dep Health Hum. Serv. Rockville, MD: https://pubs.niaaa.nih.gov/publications/ProjectMatch/match02.pdf
  20. 20.
    Kadden R, Carroll K, Donovan D, Cooney N, Monti P et al. 1995. Cognitive behavioral coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Proj. MATCH Monogr. 3, US Dep. Health Hum. Serv. Rockville, MD: https://pubs.niaaa.nih.gov/publications/ProjectMatch/match03.pdf
  21. 21.
    Nowinsky J, Baker S, Carroll K. 1992. Twelve step facilitation therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence Proj. MATCH Monogr. 1, US Dep. Health Hum. Serv. Rockville, MD: https://pubs.niaaa.nih.gov/publications/ProjectMatch/match01.pdf
  22. 22.
    Schalkwijk S, Undurraga J, Tondo L, Baldessarini RJ. 2014. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int. J. Neuropsychopharmacol. 17:1343–52
     [Google Scholar]
  23. 23.
    Skinner MD, Lahmek P, Pham H, Aubin HJ. 2014. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLOS ONE 9:e87366
     [Google Scholar]
  24. 24.
    Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD et al. 1986. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 256:1449–55
     [Google Scholar]
  25. 25.
    Jørgensen CH, Pedersen B, Tonnesen H. 2011. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin. Exp. Res. 35:1749–58
     [Google Scholar]
  26. 26.
    Am. Psychiatr. Assoc 2017. Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder Washington, DC: Am. Psychiatr. Assoc https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9781615371969
  27. 27.
    Chick J. 1999. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 20:427–35
     [Google Scholar]
  28. 28.
    Koob GF, Mason BJ. 2016. Existing and future drugs for the treatment of the dark side of addiction. Annu. Rev. Pharmacol. Toxicol. 56:299–322
     [Google Scholar]
  29. 29.
    Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K et al. 2014. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311:1889–900
     [Google Scholar]
  30. 30.
    Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP 1997. Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry 54:737–42
     [Google Scholar]
  31. 31.
    Le Magnen J, Tran G, Durlach J, Martin C. 1987. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 4:97–102
     [Google Scholar]
  32. 32.
    Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U et al. 2012. Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol. Psychiatry 71:1015–21
     [Google Scholar]
  33. 33.
    Dahchour A, de Witte P, Bolo N, Nédélec JF, Muzet M et al. 1998. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 82:107–14
     [Google Scholar]
  34. 34.
    Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M et al. 2010. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch. Gen. Psychiatry 67:1069–77
     [Google Scholar]
  35. 35.
    Nam HW, Karpyak VM, Hinton DJ, Geske JR, Ho AM et al. 2015. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. Transl. Psychiatry 5:e621
     [Google Scholar]
  36. 36.
    Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. 1998. Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet. 35:331–45
     [Google Scholar]
  37. 37.
    Wilde MI, Wagstaff AJ. 1997. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53:1038–53
     [Google Scholar]
  38. 38.
    Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L et al. 2007. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–51
     [Google Scholar]
  39. 39.
    Fink K, Meder W, Dooley DJ, Gothert M. 2000. Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol. 130:900–6
     [Google Scholar]
  40. 40.
    Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. 2004. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur. J. Neurosci. 20:1566–76
     [Google Scholar]
  41. 41.
    Mason BJ, Light JM, Williams LD, Drobes DJ. 2009. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict. Biol. 14:73–83
     [Google Scholar]
  42. 42.
    Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. 2014. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern. Med. 174:70–77
     [Google Scholar]
  43. 43.
    Mason BJ, Quello S, Shadan F. 2018. Gabapentin for the treatment of alcohol use disorder. Expert Opin. Investig. Drugs 27:113–24
     [Google Scholar]
  44. 44.
    Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J et al. 2015. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 72:757–66
     [Google Scholar]
  45. 45.
    Han B, Jones CM, Einstein EB, Powell PA, Compton WM. 2021. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry 78:922–24
     [Google Scholar]
  46. 46.
    NIAAA (Natl. Inst. Alcohol Abuse Alcohol.) 2004. NIAAA council approves definition of binge drinking NIAAA Newsl. 3 (NIH Publ. 04-5346) NIAAA Bethesda, MD:
  47. 47.
    US Dep. Agric., US Dep. Health Hum. Serv 2020. Dietary guidelines for Americans, 2020–2025 Guidel., US Dep. Agric., US Dep. Health Hum. Serv. Washington, DC: https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materials
  48. 48.
    WebMD 2022. Alcohol use disorder. WebMD https://www.webmd.com/mental-health/addiction/what-is-alcohol-abuse#1
    [Google Scholar]
  49. 49.
    US Dep. Health Hum. Serv., Off. Surg. Gen 2016. Facing addiction in America: the Surgeon General's report on alcohol, drugs, and health Rep., Off. Surg. Gen., US Dep. Health Hum. Serv. Washington, DC: https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf
  50. 50.
    Subst. Abuse Ment. Health Serv. Admin 2013. Systems-level implementation of screening, brief intervention, and referral to treatment. Tech. Assist. Publ. 13-4741 Subst. Abuse Ment. Health Serv. Admin. Rockville, MD:
     [Google Scholar]
  51. 51.
    Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB et al. 2018. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA 320:1899–909
     [Google Scholar]
  52. 52.
    Mintz CM, Hartz SM, Fisher SL, Ramsey AT, Geng EH et al. 2021. A cascade of care for alcohol use disorder: using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. Alcohol Clin. Exp. Res. 45:1276–86
     [Google Scholar]
  53. 53.
    Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. 2010. Primary care validation of a single-question alcohol screening test. J. Gen. Intern. Med. 24:783–88. Erratum. 2010. J. Gen. Intern. Med. 25:375
    [Google Scholar]
  54. 54.
    Beyer FR, Campbell F, Bertholet N, Daeppen JB, Saunders JB et al. 2019. The Cochrane 2018 review on brief interventions in primary care for hazardous and harmful alcohol consumption: a distillation for clinicians and policy makers. Alcohol Alcohol 54:417–27
     [Google Scholar]
  55. 55.
    McBain RK, Cantor JH, Eberhart NK. 2022. Estimating psychiatric bed shortages in the US. JAMA Psychiatry 79:279–80
     [Google Scholar]
  56. 56.
    Stirling S. 2014. Dying for help: Treatment options don't meet demand of growing N.J. heroin and opiate epidemic. NJ.com Jul. 27. https://www.nj.com/news/2014/07/dying_for_help_available_treatment_doesnt_meet_need_of_growing_nj_heroin_and_opiate_epidemic.html
    [Google Scholar]
  57. 57.
    US Dep. Health Hum. Serv 2020. Geographic disparities affect access to buprenorphine services for opioid use disorder Rep. OEI-12-17-00240 Off. Insp. Gen., US Dep. Health Hum. Serv. Washington, DC: https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf
  58. 58.
    Bouchery E. 2017. Examining substance use disorder treatment demand and provider capacity in a changing health care system: final report Rep., US Dep. Health Hum. Serv. Washington, DC: https://www.aspe.hhs.gov/sites/default/files/migrated_legacy_files//183121/ExamSUDfr.pdf?_ga=2.91387036.70770062.1677363640-1065095006.1585141882
  59. 59.
    Altshuler HL, Phillips PE, Feinhandler DA. 1980. Alteration of ethanol self-administration by naltrexone. Life Sci 26:679–88
     [Google Scholar]
  60. 60.
    Litten RZ, Falk DE, Ryan ML, Fertig JB. 2016. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin. Exp. Res. 40:1368–79
     [Google Scholar]
  61. 61.
    FDA (US Food Drug Admin.) 2023. Part 58: good laboratory practice for nonclinical laboratory studies. Code of Federal Regulations, Title 21: Food and Drugs Silver Spring, MD: FDA https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=58.1
    [Google Scholar]
  62. 62.
    Wessel D, Thomas C. 2023. The state of innovation in pain and addiction Rep., Biotechnol. Innov. Organ. Washington, DC: https://go.bio.org/rs/490-EHZ-999/images/BIO_The_State_of_Innovation_in_Pain_and_Addiction_2017_2022.pdf
  63. 63.
    Recovery Cent. Am 2019. Economic cost of substance abuse disorder in the United States, 2019 Rep., Recovery Cent. Am. King of Prussia, PA: https://recoverycentersofamerica.com/resource/economic-cost-of-substance-abuse-disorder-in-united-states-2019
  64. 64.
    CDC (Cent. Dis. Control Prev.) 2022. Excessive drinking is draining the U.S. economy. Centers for Disease Control and Prevention https://www.cdc.gov/alcohol/features/excessive-drinking.html
    [Google Scholar]
  65. 65.
    Doughty B, Morgenson D, Brooks T. 2019. Lofexidine: a newly FDA-approved, nonopioid treatment for opioid withdrawal. Ann. Pharmacother. 53:746–53
     [Google Scholar]
  66. 66.
    Volkow ND, Koob GF. 2015. Brain disease model of addiction: Why is it so controversial?. Lancet Psychiatry 2:677–79
     [Google Scholar]
  67. 67.
    Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. 2011. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol 46:105–12
     [Google Scholar]
  68. 68.
    Stangl AL, Earnshaw VA, Logie CH, van Brakel W, Simbayi LC et al. 2019. The health stigma and discrimination framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med 17:31
     [Google Scholar]
  69. 69.
    Subst. Abuse Ment. Health Serv. Admin 2020. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health HHS Publ. PEP20-07-01-001 Cent. Behav. Health Stat. Qual., Subst. Abuse Ment. Health Serv. Admin Rockville, MD:
  70. 70.
    Pimienta M, Dodge J, Terrault NA. 2021. The internet as a tool for liver transplant programs to combat stigma related to alcohol use disorder. Hepatol. Commun. 5:155–57
     [Google Scholar]
  71. 71.
    FDA (US Food Drug Admin.) 2015. Alcoholism: developing drugs for treatment Guid. Doc., FDA Washington, DC: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM433618.pdf
  72. 72.
    Hasin DS, Wall M, Witkiewitz K, Kranzler HR, Falk D et al. 2017. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry 4:469–76
     [Google Scholar]
  73. 73.
    Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS et al. 2017. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin. Exp. Res. 41:179–86
     [Google Scholar]
  74. 74.
    WHO (World Health Organ.) 2000. International guide for monitoring alcohol consumption and related harm Tech. Doc WHO/MSD/MSB/00.4, WHO Geneva:
  75. 75.
    Falk DE, O'Malley SS, Witkiewitz K, Anton RF, Litten RZ et al. 2019. Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiatry 76:374–81
     [Google Scholar]
  76. 76.
    Witkiewitz K, Falk DE, Litten RZ, Hasin DS, Kranzler HR et al. 2019. Maintenance of World Health Organization risk drinking level reductions and posttreatment functioning following a large alcohol use disorder clinical trial. Alcohol Clin. Exp. Res. 43:979–87
     [Google Scholar]
  77. 77.
    Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. 2005. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch. Intern. Med. 165:986–95
     [Google Scholar]
  78. 78.
    D'Onofrio G, Degutis LC. 2002. Preventive care in the emergency department: screening and brief intervention for alcohol problems in the emergency department: a systematic review. Acad. Emerg. Med. 9:627–38
     [Google Scholar]
  79. 79.
    Kaner EF, Beyer FR, Muirhead C, Campbell F, Pienaar ED et al. 2018. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst. Rev. 2:CD004148
     [Google Scholar]
  80. 80.
    NIAAA (Natl. Inst. Alcohol Abuse Alcohol.) 2023. The Healthcare Professional's Core Resource on Alcohol Bethesda, MD: NIAAA https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol
  81. 81.
    Saitz R. 2010. Alcohol screening and brief intervention in primary care: absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol. Rev. 29:631–40
     [Google Scholar]
  82. 82.
    Volkow ND, Gordon JA, Koob GF. 2021. Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology 46:2230–32
     [Google Scholar]
  83. 83.
    Hagman BT, Falk D, Litten R, Koob GF. 2022. Defining recovery from alcohol use disorder: development of an NIAAA research definition. Am. J. Psychiatry 179:807–13
     [Google Scholar]
  84. 84.
    McLellan AT, Koob GF, Volkow ND. 2022. Preaddiction—a missing concept for treating substance use disorders. JAMA Psychiatry 79:749–51
     [Google Scholar]
  85. 85.
    Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. 2016. Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders. Biol. Psychiatry 80:179–89
     [Google Scholar]
  86. 86.
    Kwako LE, Schwandt ML, Ramchandani VA, Diazgranados N, Koob GF et al. 2019. Neurofunctional domains derived from deep behavioral phenotyping in alcohol use disorder. Am. J. Psychiatry 176:744–53
     [Google Scholar]
  87. 87.
    Witkiewitz K, Stein ER, Votaw VR, Hallgren KA, Gibson BC et al. 2023. Constructs derived from the addiction cycle predict alcohol use disorder treatment outcomes and recovery 3 years following treatment. Psychol. Addict. Behav. 37:3376–89
     [Google Scholar]
  88. 88.
    Kwako L, Koob GF. 2017. Neuroclinical framework for the role of stress in addiction. Chronic Stress 1:2470547017698140
     [Google Scholar]
  89. 89.
    Koob GF. 2017. The dark side of addiction: the Horsley Gantt to Joseph Brady connection. J. Nerv. Ment. Dis. 205:270–72
     [Google Scholar]
  90. 90.
    Haber SN. 2016. Corticostriatal circuitry. Dialogues Clin. Neurosci. 18:7–21
     [Google Scholar]
  91. 91.
    Koob GF. 2020. Neurobiology of opioid addiction: opponent process, hyperkatifeia and negative reinforcement. Biol. Psychiatry 87:44–53
     [Google Scholar]
  92. 92.
    Jones DT, Graff-Radford J. 2021. Executive dysfunction and the prefrontal cortex. Continuum 27:1586–601
     [Google Scholar]
  93. 93.
    Stellar JR, Stellar E. 1985. The Neurobiology of Motivation and Reward New York: Springer-Verlag
  94. 94.
    Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr. et al. 2020. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat. Med. 26:760–68
     [Google Scholar]
  95. 95.
    Koob GF. 2008. A role for brain stress systems in addiction. Neuron 59:11–34
     [Google Scholar]
  96. 96.
    Koob GF. 2015. The dark side of emotion: the addiction perspective. Eur. J. Pharmacol. 753:73–87
     [Google Scholar]
/content/journals/10.1146/annurev-pharmtox-031323-115847
Loading
Alcohol Use Disorder Treatment: Problems and Solutions
Annual Review of Pharmacology and Toxicology 64, 255 (2024); https://doi.org/10.1146/annurev-pharmtox-031323-115847
/content/journals/10.1146/annurev-pharmtox-031323-115847
/content/journals/10.1146/annurev-pharmtox-031323-115847
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error